Evaluation of plasmin system factors in COVID-19 patients with ischemic heart disease

Abstract

Evaluation of the activity of plasmin system’s factor type 1 plasminogen activator inhibitor (PAI-1). PAI-1 is important for early prediction of disease progression and possible thrombogenic complications in patients with CAD and COVID-19. The study included 32 patients with coronary CAD receiving inpatient treatment with a diagnosis of COVID-19 at the “ATLAS” distribution center and 28 currently healthy people. In the main group, 71.8% (23 out of 32) of patients had an increased level of PAI-1 in the blood plasma and a significantly reduced level of plasminogen in the same patients. Risk factors such as obesity, anxiety and depression syndrome, and hypercholesterolemia have been identified in patients with high PAI-1 levels. In practically healthy subjects, adverse changes in PAI-1 and plasminogen were not observed. Evaluation of systemic plasmin factors in patients infected with COVID-19 and suffering from coronary artery disease may be an important link in the selection of adequate anticoagulants for the prevention of thrombogenic complications.